Drug intelligence / Profile preview

Autologous regulatory T Cell Product (Guy's and St Thomas' NHS Foundation Trust)

Development stage
Phase 2
Lead developer
Guy's and St Thomas' NHS Foundation Trust
Modality
Cell Therapies
Administration
Intravenous
01

Overview

This autologous cell therapy consists of polyclonal naturally occurring regulatory T cells (nTregs) that are isolated from a patient and expanded ex vivo. Developed by Guy's and St Thomas' NHS Foundation Trust in collaboration with King's College London, the product is intended to prevent graft rejection in living-donor kidney transplant recipients. The therapy works by modulating the recipient's immune system to favor graft tolerance, potentially allowing for a reduction in standard maintenance immunosuppression. In clinical trials (notably 'The ONE Study'), the infusion of these cells post-transplantation was shown to be safe and associated with high rates of rejection-free survival compared to standard care.

Other names
nTreg therapyAutologous naturally occurring regulatory T cellsPolyclonal regulatory T cell therapy
02

Targets

NeuraminidaseIL-2 (Interleukin 2)MHC II (Major histocompatibility complex class II receptor)

Beyond the preview

Go deeper on Autologous regulatory T Cell Product (Guy's and St Thomas' NHS Foundation Trust).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Autologous regulatory T Cell Product (Guy's and St Thomas' NHS Foundation Trust).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call